@entity6817 treatment alters serum n-3 to n-6 XXXX ratio in @entity1 with @entity2299 .

@entity1 @entity5204 @entity7784 @entity8393 @entity2299 @entity4600 @entity8671 @entity1426 @entity1474 @entity4601 @entity2452 @entity6817
BACKGROUND: The effects of statins on serum n-3 to n-6 @entity1474 ( @entity5204 ) levels have not been fully evaluated. We examined the effects of two types of @entity6817 ( @entity8671 and @entity2452 ) on serum @entity5204 levels and their ratios in @entity1 with @entity2299 . FINDINGS: A total of 46 @entity1 who were not receiving lipid-lowering therapy were randomly assigned to receive either 2.5  mg/day of @entity8671 or 2  mg/day of @entity2452 . Serum @entity5204 levels were measured at baseline, at 4  weeks, and at 12  weeks. @entity8671 was used to treat 23 @entity1 , and the remaining 23 @entity1 were treated using @entity2452 . Serum @entity4600 ( @entity4601 ) levels decreased significantly at 12  weeks in both groups ( @entity8671 : from 169.6 to 136.3   g/mL, p   =   0.006; @entity2452 : from 188.6 to 153.9   g/mL, p   =   0.03). However, serum levels of @entity7784 ( @entity8393 ) and @entity1426 (AA) did not change. In addition, the @entity8393 /AA ratio did not change, whereas the @entity4601 /AA ratio decreased significantly at 12  weeks in both groups ( @entity8671 : from 0.99 to 0.80, p   =   0.01; @entity2452 : from 1.14 to 0.91, p   =   0.003). No adverse events were observed during the study period. CONCLUSIONS: In this small, open-label, pilot study, @entity8671 and @entity2452 decreased serum @entity4601 levels and the @entity4601 /AA ratio in @entity1 with @entity2299 .
